XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating Expenses:        
Research and development $ 3,675 $ 3,399 $ 12,999 $ 9,600
General and administrative 1,548 1,062 3,791 3,687
Total operating expenses 5,223 4,461 16,790 13,287
Loss from operations (5,223) (4,461) (16,790) (13,287)
Other income (expense):        
Grant income 3,037 3,192 12,375 8,146
Change in the fair value of the derivative liability   (112) 2,209 135
Change in the fair value of the warrant liability   1   33
Change in the fair value of the Simple Agreements for Future Equity (932)   (1,976)  
Other income, net 8 95 256 353
Gain (loss) on debt extinguishment     443 (129)
Interest expense, net   (506) (894) (1,222)
Total other income, net 2,113 2,670 12,413 7,316
Net loss (3,110) (1,791) (4,377) (5,971)
Cumulative preferred stock dividends (1,859) (1,064) (4,326) (3,170)
Net loss attributable to common stockholders (4,969) (2,855) (8,703) (9,141)
Unrealized (loss) gain on foreign currency translation (3) 18 (9) (40)
Total comprehensive loss $ (3,113) $ (1,773) $ (4,386) $ (6,011)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (8.12) $ (5.31) $ (14.87) $ (18.34)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (8.12) $ (5.31) $ (14.87) $ (18.34)
Weighted-average common shares outstanding, basic (in shares) 611,680 537,315 585,320 498,415
Weighted-average common shares outstanding, diluted (in shares) 611,680 537,315 585,320 498,415